提吉特
封锁
抗体
Treg细胞
髓系细胞
髓样
医学
免疫学
T细胞
内科学
免疫系统
受体
白细胞介素2受体
作者
Xiangnan Guan,Ruozhen Hu,Yoonha Choi,Shyam Srivats,Barzin Y. Nabet,John Silva,Lisa McGinnis,Robert L. Hendricks,Katherine Nutsch,Karl L. Banta,Ellen Duong,Alexis Dunkle,Patrick Chang,Chia-Jung Han,Stephanie Mittman,Nandini Molden,Pallavi Daggumati,Wendy Connolly,Melissa L. Johnson,Delvys Rodríguez‐Abreu
出处
期刊：Nature
[Nature Portfolio]
日期：2024-02-28
卷期号：627 (8004): 646-655
被引量：24
标识
DOI：10.1038/s41586-024-07121-9
摘要
Tiragolumab, an anti-TIGIT antibody with an active IgG1κ Fc, demonstrated improved outcomes in the phase 2 CITYSCAPE trial (ClinicalTrials.gov: NCT03563716 ) when combined with atezolizumab (anti-PD-L1) versus atezolizumab alone
科研通智能强力驱动
Strongly Powered by AbleSci AI
cdercder
hjyylab
wangrblzu
挖掘机
孙燕
coolkid
昏睡的蟠桃
彭于彦祖
iNk
jenningseastera
SYLH
小粽子
OCDer
FelixChen
从容芮
Singularity
Kiosta
elizabeth339
个性归尘
可千万不要躺平呀
皖公网安备34019202002308
